# Q24 Arm C Chairman synthesis
# salvaged_from_context: false
# chairman_model: sonnet-4.6 (spawned subagent — main thread was opus-4-8 this session; model parity preserved per spec §2 + HISTORY rule)
# council: 5 sonnet-4.6 members (Empiricist, Theorist, Methodologist, Integrator, Devil's Advocate) + 5 haiku-4.5 reviewers + sonnet-4.6 chairman subagent
# stage2 aggregate: Integrator 17.0 (top), Methodologist 16.8, Theorist 16.4, Empiricist 14.6, DA 13.2 (bottom). GENUINE narrow-vs-broad generalization split preserved. Standard tier — no debate.
# reviewer note: part of the 7/10 first-pass refusal wave; recovered via neutral grading-frame retry.

## Council answer

The most useful organizing frame here is the Theorist's direction-vs-magnitude decoupling: these are two separate questions with different answers, and conflating them is where most generalization errors happen.

**Direction (~85% confidence):** The finding that this diet class lowers LDL in middle-aged adults is credible and probably generalizes broadly. Cholesterol metabolism — dietary fat, fiber, and sterols affecting hepatic LDL-receptor activity — is a well-established biological mechanism, not a cultural artifact. The RCT confirms the mechanism operates in a real-world sample. You can act on this directional signal now.

**Magnitude (low confidence, ~25-35%):** The 12-point number does not travel freely. Do not plug it into a cost-effectiveness model as a fixed parameter. The true replicable effect is likely somewhere between 0 and 12 — probably 5-9 points — once you account for:

- Winner's curse: small-sample RCTs systematically overestimate effect sizes
- Adherence decay: 8-week researcher-contact compliance collapses in real-world settings; discount 30-50% for this alone
- Baseline diet delta: effect size in diet trials is almost entirely a function of how bad the starting diet was; this city's food environment is not your patient's
- N=80 underpowering: the true CI is plausibly 4-20 points wide; male subgroup is roughly 20-25 people, which is noise

**Generalization tiers — what's safe and what isn't:**

| Tier | Confidence |
|---|---|
| Direction generalizes to broadly similar metabolic populations | Medium-high |
| Magnitude applies to women 40-55 in similar dietary contexts | Low-medium |
| Magnitude applies to men, older/younger cohorts, non-Western diets | Very low |
| 8-week reduction predicts durable long-term effect | Very low |

**What to do:** Treat this as a hypothesis-confirming signal, not a practice-changing one. Recommend the intervention as a trial-worthy option for patients outside the studied demographic while flagging that the magnitude may vary substantially. Do not withhold it pending perfect data, but do not quote 12 points to patients or payers. The next necessary step is a multi-site RCT (N≥300), sex-balanced, 6+ month follow-up, pre-registered subgroup analyses.

## Dissent worth keeping

**Devil's Advocate (stated at full strength):**

The reflexive "small/narrow sample, can't generalize" response is itself a bias that destroys useful signal. An 8-week RCT of 80 people is a completed randomized controlled trial, not a pilot. Cholesterol metabolism is not culturally constructed. A 12-point reduction is clinically meaningful — roughly equivalent to a low-dose statin effect. The concrete failure mode of over-conservatism: you wait for the perfect multi-site, age-balanced, 2,000-person trial that takes 7 years and $40M to fund, while a real, low-risk dietary intervention that could reduce cardiovascular events in millions sits on a shelf. Clinicians who dismiss every adequately-powered RCT on demographic grounds default to pharmaceutical interventions with far thinner mechanistic justification. Generalize the direction and plausibility broadly and immediately; apply demographic caveats only to the effect size; recommend as trial-worthy now rather than withholding pending fuller evidence.

**DA's own conceded weakness:** If the intervention works partly through gut-microbiome modulation — and microbiome composition varies substantially by geography, ethnicity, and prior diet (it does) — then the single-city homogeneity is a genuine confounder, not just a demographic checkbox. The "mechanism is universal" argument has a real ceiling.

*The peer-review panel credited the over-conservatism-is-harmful point as genuinely important while rating DA lowest for underweighting the N=80 magnitude problem and dismissing the microbiome/geography issue too quickly.*

## Confidence

Medium-low, with a genuine council split. The council reached consensus on the direction-vs-magnitude decoupling but split clearly on practical implication: narrow-generalizers (Empiricist, Methodologist, Integrator) want replication before widening application; the Theorist occupies a middle position that the direction is credible but the number isn't portable; the Devil's Advocate argues the field's default over-conservatism actively harms patients and that cautious application now beats waiting. That split is not resolved — it reflects a real and legitimate disagreement about how to act under uncertainty with asymmetric costs.
